In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells(660 views) Pisano M, De Paola I, Nieddu V, Sassu I, Cossu S, Galleri G, Del Gatto A, Budroni M, Cossu A, Saviano M, Palmieri G, Zaccaro L, Rozzo C
Anticancer Res (ISSN: 0250-7005, 0250-0700, 1791-7530electronic), 2013 Mar; 33(3): 871-879.
Keywords: Cell Adhesion, Cell Migration, Integrin V 3, Malignant Melanoma, Rgd Peptide, Antineoplastic Agent, Rgdechi Hcit, Unclassified Drug, Vitronectin Receptor, Antineoplastic Activity, Article, Cell Proliferation, Cytofluorometry, Human, Human Cell, In Vitro Study, Melanoma Cell, Priority Journal, Protein Expression, Angiogenesis Inhibitors, Cell Line, Tumor, Cell Movement, Integrin Alphavbeta3, Integrin Av 3, Pharmacology, Drug Effects, Analysis, Antagonists, Drug Therapy, Pathology, Secondary,
Affiliations: *** IBB - CNR ***
Institute of Biomolecular Chemistry-National Research Council of Italy, Traversa La Crucca 3, 07100 Sassari, Italy
Institute of Biostructures and Bioimaging-National Research Council of Italy, Napoli, Italy
Sardinia Research Laboratories Porto Conte Ricerche, Alghero, Italy
Service of Epidemiology, Local Health Unit 1, Sassari, Italy
Institute of Pathology, University Health Unit, Sassari, Italy
Institute of Crystallography-National Research Council of Italy, Bari, Italy
Istituto di Chimica Biomolecolare-CNR, Traversa La Crucca 3, 07100 Sassari, Italy. marina.pisano@icb.cnr.it,
References: Not available.
In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells
Background: In malignant melanoma (MM), overexpression of alpha (v) beta (3) integrin is linked to a more metastatic phenotype. Development of anti-alpha (v) beta (3) agents able to counteract melanoma progression would be helpful for disease treatment. A new selective ligand of alpha (v) beta (3), RGDechi-hCit, has anti-angiogenic properties against endothelial cells in animal angiogenesis models. The aim of this study was to evaluate the in vitro effects of the RGDechi-hCit peptide on MM cell lines. Materials and Methods: Cytofluorimetric analysis characterized the cell surface expression of alpha (v) beta (3) integrin on seven MM cell lines: A375, WM266-4, SK-Mel-28, Sbcl2, LB24Dagi, PR-Mel and PNP-Mel. Cell proliferation, adhesion, and migration assays were carried out using the alpha (v) beta (3) -antagonist RGDechi-hCit. Results: Proliferation was not significantly inhibited by RGDechi-hCit, although striking morphological changes were detected in MM cell lines highly expressing alpha (v) beta (3). Conversely, assays on fibronectin-coated plates showed a significant RGDechi-hCit dose-dependent inhibitory effect on both adhesion and migration. Conclusion: The data demonstrate anti-adhesion and anti-migration, but not antiproliferative, activities of RGDechi-hCit against MM cells
In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(433 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote